- H.E Dr. Jean Kaseya, Director General of the African Centers for Disease Control and Prevention (Africa CDC), visited SK bioscience to discuss the vaccine localization program in the African continent.
- SK bioscience introduced the ‘Glocalization Project’ which is transplanting R&D and manufacturing capabilities to countries that lack sufficient vaccine infrastructures.
SEONGNAM, South Korea, Nov. 5, 2023 /PRNewswire/ — SK bioscience, an innovative vaccine and biotech company committed to promoting human health from prevention to cure, announced that H.E Dr. Jean Kaseya, Director General of Africa CDC visited SK bioscience headquarters on November 3 to discuss collaboration with the Partnerships for African Vaccine Manufacturing (PAVM).
Dr. Kaseya was appointed as the Director General of Africa CDC in February 2023. Currently, he is visiting partners to foster partnerships and closer collaboration on African public health matters, with a particular focus on local manufacturing.
The PAVM, established by the African Union (AU) in 2021, aims to achieve an ambitious goal. It seeks to enable the African vaccine manufacturing industry to produce, and supply over 60 percent of the total vaccine doses required on the continent by 2040. This represents a significant increase from the current level, which is less than 1 percent. There are also interim goals of reaching 10 percent by 2025 and 30 percent by 2030.
Africa CDC plans to secure a vaccine portfolio to respond to various diseases including tuberculosis, hepatitis B, HIV, malaria, Ebola, and unknown infectious diseases (Disease X). This will be achieved through the formation of strategic partnerships with global companies and the establishment of vaccine research and development (R&D) and manufacturing infrastructures, including local plants and cold chain logistics.
SK bioscience introduced the ‘Glocalization Project,’ a mid to long term core strategy that involves transferring R&D and manufacturing capabilities to countries with insufficient vaccine infrastructure to support the PAVM.
In July, SK bioscience signed an agreement with the Government Pharmaceutical Organization (GPO), a state pharmaceutical enterprise in Thailand, to strengthen the vaccine infrastructure. In September, they signed a memorandum of understanding (MOU) with the Republic of Serbia to establish a strategic partnership in vaccine development and manufacturing.
After the discussion session, Dr. Kaseya and the visiting members toured SK bioscience’s R&D Center to observe the know-hows in vaccine development.
H.E Dr. Jean Kaseya, Director General of Africa CDC said, “I had an opportunity to learn about SK bioscience’s Glocalization Project at the Regionalized Vaccine Manufacturing Collaborative, hosted in Geneva last May. Today’s visit holds great significances as it allows us to delve deeper into the Glocalization Project and tour the R&D facility. Africa’s New Public Health Order calls to expand manufacturing of vaccines, diagnostics, and therapeutics. We’re actively seeking partnerships, particularly in the area of R&D to help us achieve the PAVM’s ambitious goals.”
Jaeyong Ahn, CEO of SK bioscience said, “The Glocalization Project is an innovative business model that goes beyond merely establishing local plants. It addresses the inequality of vaccine supply and enables a rapid response to new pandemics. Through collaboration with governments, institutions, and companies, we aim to lead efforts in preventing future pandemics.”
About SK bioscience
SK bioscience is an innovative vaccine and biotech company, committed in vaccine development and manufacturing to enable more equitable access of vaccines in the world. In leveraging strengths on cutting-edge technologies, SK bioscience has been dedicated to promoting human health from prevention to cure across the globe. With cooperation of domestic and international governments, regulatory agencies, healthcare providers, doctors and medical experts, all of the SK colleagues are passionately committed to providing high-quality vaccines to those who need them and better public healthcare solutions.
– SK bioscience Website
– SK bioscience Linkedin
About the African Centers for Disease Control and Prevention (Africa CDC)
The Africa Centres for Disease Control and Prevention (Africa CDC) is a continental autonomous Public Health agency of the African Union which supports Member States in their efforts to strengthen health systems and improve surveillance, emergency response, prevention, and control of diseases.
For more information, visit https://africacdc.org/
Contact
SK bioscience Communications Team
Changhyun Jin(jin99@sk.com)
Jeannie S. Pak(J.pak@sk.com)
Tae-Gyun Kim(taegyunkim@sk.com)
View original content:https://www.prnewswire.co.uk/news-releases/africa-cdc-director-general-visits-sk-bioscience-to-discuss-vaccine-localization-in-africa-301977822.html
